Valuation : Kanaph Therapeutics Inc.

Market Cap 207B 154M 133M 125M 114M 213M 14.55B 214M 1.47B 572M 7.46B 579M 566M 24.04B P/E 2025
-2.8x
P/E 2026 * -
Enterprise Value 207B 154M 133M 125M 114M 213M 14.55B 214M 1.47B 572M 7.46B 579M 566M 24.04B EV / Sales 2025
37.3x
EV / Sales 2026 * 42.2x
Free-Float
64.31%
Yield 2025 *
-
Yield 2026 * -
Manager TitleAgeSince
Chief Executive Officer - 01/05/2019
Chief Tech/Sci/R&D Officer 47 01/01/2021
Chief Tech/Sci/R&D Officer 55 01/08/2019
Director TitleAgeSince
Director/Board Member - 01/05/2019
Director/Board Member 53 01/04/2019
Director/Board Member 48 01/09/2023
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 154M
-2.54%-2.84%-1.77%+14.72% 48.93B
-0.40%+1.03%+418.57%+523.39% 45.01B
-1.42%+2.30%+42.67%+21.22% 44.07B
-1.22%-2.31%+4.82%+74.90% 40.73B
+0.53%-1.36%+16.87%+47.12% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+123.04% 16.5B
-1.01%+0.50%+13.91%+31.45% 14.67B
-1.65%-1.03%+75.93%+41.22% 13.77B
Average -0.83%+0.48%+74.05%+109.63% 27.51B
Weighted average by Cap. -1.03%+0.11%+89.42%+127.93%

Financials

2025 2026 *
Net sales 5.56B 4.13M 3.55M 3.34M 3.05M 5.71M 390M 5.73M 39.5M 15.33M 200M 15.51M 15.17M 644M 4.92B 3.65M 3.14M 2.95M 2.7M 5.05M 345M 5.06M 34.92M 13.55M 177M 13.7M 13.41M 570M
Net income - -
Net Debt - -
Logo Kanaph Therapeutics Inc.
Kanaph Therapeutics Inc is a Korea-based company primarily engaged in the research and development of pharmaceutical products. The Company is engaged in the research and development of anticancer drugs and ophthalmic disease treatments based on human genome-based drug discovery technologies. The Company primarily researches and develops bispecific antibodies including immuno-oncology and ophthalmic disease treatments, targeted anticancer antibody-drug conjugate (ADC) new drugs and ADC platform technologies. The Company also provides synthetic new drugs including immuno-oncology drugs and targeted anticancer drugs.
Employees
-

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A0082N0 Stock